基本資料

投資策略

基因治療主題，亦即子基金之聚焦主題，投資於全球曝露於基因療法主題之公司，以期獲得報酬。與致力於追求增進永續性及提倡良好健康與福祉之社會責任型財務的全球通則一致。雖然子基金不受限於任何產業，但會對特定產業或市場(例如醫療及生物科技)持有重大投資部位。子基金可能會將其大部分資產投資於小型公司，且隨時於特定產業或市場持有重大投資部位。

至少 51% 之資產將投資於具有積極環境及／或社會特性的公司，且該等公司遵循良好的公司治理慣例，此係透過投資經理人專有的ESG 評分方法及／或第三方資料衡量之。

基金經理人

• Romahi Yazann
• 資歷 5年(2019-10-25 至今)

• Yazann Romahi, PhD, CFA, Managing Director, is CIO for Quantitative Beta Strategies focused on further developing the firm's factor-based franchise across both alternative beta and strategic beta. Prior to that he was Head of Research and Quantitative Strategies in Multi Asset Solutions, responsible for the quantitative models that help establish the broad asset allocation reflected across Multi-Asset Solutions portfolios globally.

• Hussain Aijaz
• 資歷 5年(2019-10-25 至今)

• Aijas Hussain,Vice President, is a portfolio analyst in the Quantitative Beta Strategies group, based in London. Prior to joining J.P. Morgan Asset Management in 2016, Aijaz worked as an Analytics Consultant at FactSet Research Systems. Aijaz graduated from Imperial College London with a BSc in Mathematics.

基金費用

聯絡資訊